• Explore /
  • Poster
  • / Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.

Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: Interim results of the phase 2 CARSKIN trial.

Abstract Poster

Authors

null

Eve Maubec

AP-HP Dermatology department, Avicenne hospital, Université Paris 13, Bobigny, France

Eve Maubec , Marouane Boubaya Sr., Peter Petrow , Nicole Basset-Seguin , Jean-Jacques Grob , Brigitte Dreno , Isabelle Scheer-Senyarich Sr., Sabine Helfen Sr., Julie De Quatrebarbes , Elodie Poirier , Lydia Deschamps , Céline Alloux , Isabelle Lopez , Soufian Cherbal , Marie Thérèse Leccia , Marie Beylot-Barry , Florent Grange , Olivier Schischmanoff , Annick Tibi , Vincent Levy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02883556

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9534)

DOI

10.1200/JCO.2018.36.15_suppl.9534

Abstract #

9534

Poster Bd #

361

Abstract Disclosures

Similar Posters

First Author: Eve Maubec

First Author: Margarita Majem

First Author: Eve Maubec

First Author: Dean F. Bajorin